General Information
Baloxavir Marboxil API is a cap-dependent endonuclease inhibitor that impedes the growth and spread of influenza virus in its finished dose. Baloxavir Marboxil specifically targets and binds to the influenza polymerase acidic (PA) protein, inhibiting its CEN activity. This inhibition of PA endonuclease halts the replication of influenza virus mRNA, resulting in a reduction of viral load. It was approved for medical use both in Japan and in the United States in 2018.
About the API
Systematic name
({(12aR)-12-[(11S)-7,8-Difluoro-6,11-dihydrodibenzo[b,e]thiepin-11-yl]-6,8-dioxo- 3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin-7- yl}oxy)methyl methyl carbonate
Trade name(s)
Xofluza
Technology
Synthetic
Molecular Formula
C27H23F2N3O7S
Molecular Weight
571.55 g/mol
Physical properties
White to yellowish
Therapeutic category
Antiviral
Available formulations
Oral Liquid
Oral Solid